SAREPTA THERAPEUTICS, INC. (SRPT) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 105.63M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 105.63M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 105.63M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 105.63M | (m) | (m) |
| 2026-03-31 | 105.58M | (m) | (m) |
| 2025-12-31 | 104.99M | (m) | (m) |
| 2025-09-30 | 104.79M | (m) | (m) |
| 2025-06-30 | 97.71M | (m) | (m) |
| 2025-03-31 | 98.28M | (m) | (m) |
| 2024-12-31 | 97.03M | (m) | (m) |
| 2024-09-30 | 95.52M | (m) | (m) |
| 2024-06-30 | 95.37M | (m) | (m) |
| 2024-03-31 | 94.52M | (m) | (m) |
| 2023-09-30 | 93.55M | (m) | (m) |
| 2023-06-30 | 93.28M | (m) | (m) |
| 2023-03-31 | 93.15M | (m) | (m) |
| 2022-12-31 | 87.98M | (m) | (m) |
| 2022-09-30 | 87.78M | (m) | (m) |
| 2022-06-30 | 87.57M | (m) | (m) |
| 2022-03-31 | 87.50M | (m) | (m) |
| 2021-12-31 | 87.15M | (m) | (m) |
| 2021-09-30 | 87.08M | (m) | (m) |
| 2021-06-30 | 79.84M | (m) | (m) |
| 2021-03-31 | 79.77M | (m) | (m) |
| 2020-12-31 | 79.42M | (m) | (m) |
| 2020-09-30 | 78.91M | (m) | (m) |
| 2020-06-30 | 78.51M | (m) | (m) |
| 2020-03-31 | 77.99M | (m) | (m) |
| 2019-09-30 | 74.54M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |